Home  /  Resource Library  /  A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study)

A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study)

Results of a phase III study examining ofatumumab combined with bendamustine for treatment of relpased indolent lymphomas.